CIPLA.NS vs. LLY
CIPLA.NS (Cipla Limited) and LLY (Eli Lilly and Company) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, CIPLA.NS returned 12.18%/yr vs 37.47%/yr for LLY. At a 0.01 correlation, their price movements are largely independent.
Performance
CIPLA.NS vs. LLY - Performance Comparison
Loading charts...
Different Trading Currencies
CIPLA.NS is traded in INR, while LLY is traded in USD. To make them comparable, the LLY values have been converted to INR using the latest available exchange rates.
Returns By Period
In the year-to-date period, CIPLA.NS achieves a -9.01% return, which is significantly lower than LLY's 7.30% return. Over the past 10 years, CIPLA.NS has underperformed LLY with an annualized return of 12.18%, while LLY has yielded a comparatively higher 37.47% annualized return.
CIPLA.NS
- 1D
- -0.30%
- 1M
- 3.01%
- YTD
- -9.01%
- 6M
- -8.81%
- 1Y
- -5.66%
- 3Y*
- 13.52%
- 5Y*
- 8.57%
- 10Y*
- 12.18%
LLY
- 1D
- 1.53%
- 1M
- 12.38%
- YTD
- 7.30%
- 6M
- 11.18%
- 1Y
- 61.65%
- 3Y*
- 42.52%
- 5Y*
- 48.98%
- 10Y*
- 37.47%
CIPLA.NS vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CIPLA.NS Cipla Limited | -9.01% | -0.10% | 23.72% | 16.77% | 14.52% | 15.78% | 73.26% | -7.42% | -14.21% | 7.36% |
LLY Eli Lilly and Company | 7.30% | 46.96% | 37.34% | 62.02% | 48.69% | 69.38% | 34.34% | 19.09% | 53.17% | 10.51% |
Correlation
The correlation between CIPLA.NS and LLY is -0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.05 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.03 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.01 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.02 |
Correlation (All Time) Calculated using the full available price history since Jul 3, 2007 | 0.01 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CIPLA.NS vs. LLY — Risk / Return Rank
CIPLA.NS
LLY
CIPLA.NS vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cipla Limited (CIPLA.NS) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CIPLA.NS | LLY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.91 | ||
| Sortino ratioReturn per unit of downside risk | -2.46 | ||
| Omega ratioGain probability vs. loss probability | 0.97 | 1.31 | -0.34 |
| Calmar ratioReturn relative to maximum drawdown | -0.20 | 2.76 | -2.96 |
| Martin ratioReturn relative to average drawdown | -0.41 | 7.78 | -8.19 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CIPLA.NS | LLY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.27 | 1.64 | -1.91 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.38 | 1.50 | -1.12 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.48 | 1.25 | -0.77 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.04 | 0.94 | -0.90 |
Drawdowns
CIPLA.NS vs. LLY - Drawdown Comparison
The maximum CIPLA.NS drawdown since its inception was -99.02%, which is greater than LLY's maximum drawdown of -36.23%. Use the drawdown chart below to compare losses from any high point for CIPLA.NS and LLY.
Loading charts...
Drawdown Indicators
| CIPLA.NS | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.02% | -36.23% | -62.79% |
Max Drawdown (1Y)Largest decline over 1 year | -28.32% | -22.44% | -5.88% |
Max Drawdown (3Y)Largest decline over 3 years | -28.32% | -32.61% | +4.29% |
Max Drawdown (5Y)Largest decline over 5 years | -28.32% | -32.61% | +4.29% |
Max Drawdown (10Y)Largest decline over 10 years | -43.40% | -32.61% | -10.79% |
Current DrawdownCurrent decline from peak | -17.34% | -4.61% | -12.73% |
Average DrawdownAverage peak-to-trough decline | -52.85% | -9.05% | -43.80% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.74% | 7.95% | +5.79% |
Volatility
CIPLA.NS vs. LLY - Volatility Comparison
Cipla Limited (CIPLA.NS) and Eli Lilly and Company (LLY) have volatilities of 9.87% and 9.66%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CIPLA.NS | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.87% | 9.66% | +0.21% |
Volatility (6M)Calculated over the trailing 6-month period | 16.20% | 26.80% | -10.60% |
Volatility (1Y)Calculated over the trailing 1-year period | 20.79% | 37.88% | -17.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.04% | 32.80% | -9.76% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.79% | 30.08% | -4.29% |
Dividends
CIPLA.NS vs. LLY - Dividend Comparison
CIPLA.NS's dividend yield for the trailing twelve months is around 1.16%, more than LLY's 0.60% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CIPLA.NS Cipla Limited | 1.16% | 1.06% | 0.85% | 0.68% | 0.46% | 0.53% | 0.49% | 0.63% | 0.58% | 0.33% | 0.35% | 0.31% |
LLY Eli Lilly and Company | 0.60% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Financials
CIPLA.NS vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Cipla Limited and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CIPLA.NS and LLY have a correlation of -0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for CIPLA.NS and LLY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer